<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="style.css">
    <title>Antigenic Characterisation of Alphaviruses - Research Poster</title>
</head>

<body>
    <!-- Navigation Bar -->
    <nav class="navbar">
        <div class="nav-left">
            <span class="logo">SCIE3121</span>
        </div>
        <button class="menu-toggle" id="menuToggle">
            <span></span>
            <span></span>
            <span></span>
        </button>
        <ul class="nav-links" id="navLinks">
            <li><a href="#home" class="nav-item">Poster</a></li>
            <li><a href="#background-section" class="nav-item">Background</a></li>
            <li><a href="#methods-section" class="nav-item">Methods</a></li>
            <li><a href="#results-section" class="nav-item">Results & Key Findings</a></li>
            <li><a href="#future-section" class="nav-item">Future Directions</a></li>
        </ul>
    </nav>

    <!-- Hero Section - Poster Title -->
    <section class="hero_section" id="home">
        <div class="section_container">
            <div class="hero_container">
                <div class="text_section">
                    <h1>Antigenic Characterisation of Pathogenic and Chimeric Alphaviruses Using a Novel Insect-Specific Platform</h1>
                    <p class="subtitle">Research Project | SCIE3121</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Main Poster Content -->
    <section class="poster_content" id="poster">
        <div class="section_container">
            <!-- Research Highlights Grid -->
            <div class="poster_grid">
                <!-- Background -->
                <div class="poster_card">
                    <h3>Background</h3>
                    <p>
                        ...
                    </p>
                </div>

                <!-- Objectives -->
                <div class="poster_card">
                    <h3>Aims</h3>
                    <p>1) Evaluate the potential of 11F4 as a pan-alphavirus antibody <br>
                    2) Antigenic Characterization of Chimeric Alphaviruses.</p>
                </div>

                <!-- Methods -->
                <div class="poster_card">
                    <h3>Methods</h3>
                    <p> 
                        Circular Polymerase Extension Reaction (CPER) was use to generate infectious virus clones.<br>
                     Enzyme-linked immunosorbent assays (ELISAs) were used to assess the binding afinity of antibodies to chimeric viruses and their wild-type counterparts as well as determine the concentration of new virus stocks. </p>
                </div>

                <!-- Results -->
                <div class="poster_card">
                    <h3>Key Findings</h3>
                    <p>Preliminary results reveal...</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Background Section -->
    <section class="detail_section" id="background-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Background & Literature Review</h2>

                <div class="content_section">
                    <h3>Alphavirus Overview</h3>
                    <p>
                    <li>In recent years, Chikungunya fever outbreaks have been affecting Central and East Africa, Southeast Asia, and South America. It is estimated that 104 countries have experienced CHIKV transmission, with 35 million infections annually. Despite its burden on public health, the first CHIKV vaccines were only recently licensed. The major hurdle in the development in vaccines was the limited understanding of the underlying circulation of CHIKV globally. This knowledge gap was driven by frequent misdiagnosis with other pathogens, such as dengue or influenza, and limited access to confirmatory laboratory testing in endemic regions. <br> 
                    </li>
                    <li>Due to overlapping clinical manifestations, a definitive alphavirus diagnosis relies on diagnostic tests dependent on the phase of the infection such as culture, molecular, and serological assays, with the current gold standard being RT-PCR; however, this requires a laboratory, equipment, and technical training. This is problematic as developing countries may not have consistent electricity, emphasizing the need for an accessible, affordable, and rapid diagnostic tools.</li>
                    </p>
                    
                    <div class="highlight_box">
                        <h4>Key Characteristics:</h4>
                        <p>• Approximately 70 nm diameter<br>
                        • Positive-sense, single-stranded RNA genome (~11.7 kb)<br>
                        • Transmitted primarily by mosquito and tick vectors<br>
                        • Can cause acute febrile illness, arthralgia, and encephalitis</p>
                    </div>
                </div>

                <div class="content_section">
                    <h3>Clinical Significance</h3>
                    <p>Several alphaviruses pose significant public health concerns:</p>
                    <ul>
                        <li><strong>Chikungunya Virus (CHIKV):</strong> Emerging pathogen causing epidemic polyarthralgia, affecting millions globally</li>
                        <li><strong>Eastern Equine Encephalitis (EEE):</strong> High mortality rate (~30%) with severe neurological manifestations</li>
                        <li><strong>Venezuelan Equine Encephalitis (VEE):</strong> Potential agricultural impact with high mortality in equines</li>
                        <li><strong>Ross River Virus (RRV):</strong> Common arthritis-causing virus in Australia and Pacific regions</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Antigenic Properties</h3>
                    <p>Viral antigens are critical for immune recognition and vaccine development. Key antigenic components include:</p>
                    <ul>
                        <li><strong>Envelope Proteins (E1 and E2):</strong> Primary targets for neutralising antibodies</li>
                        <li><strong>Non-structural Proteins (nsP1-nsP4):</strong> Involved in viral replication and immune evasion</li>
                        <li><strong>Capsid Protein:</strong> Structural antigen recognised in some immune responses</li>
                    </ul>
                    <p>Antigenic variation between strains influences viral pathogenesis, transmissibility, and vaccine efficacy.</p>
                </div>

                <div class="content_section">
                    <h3>Vaccine Development Challenges</h3>
                    <p>Despite their public health importance, no approved vaccines exist for most alphaviruses. Key challenges include:</p>
                    <ul>
                        <li>Understanding precise antigenic epitopes for vaccine design</li>
                        <li>Balancing immunogenicity with safety</li>
                        <li>Managing antigenic drift and population heterogeneity</li>
                        <li>Cost-effective production platforms</li>
                    </ul>
                </div>

                <div class="content_section">

                    <div class="highlight_box">
                        <h4>Project Aims:</h4>
                        <p> 
                        1) Evaluate the potential of 11F4 as a pan-alphavirus antibody.<br>
                        2) Antigenic Characterization of Chimeric Alphaviruses.
                        </p>
                    </div>
                </div>

                <div class="content_section">
                    <h3>Insect-Specific Viruses as Platforms</h3>
                    <p> 
                    Previous studies have extensively explored the use of insect-specific flaviviruses.
                    </p>
                </div>
            </div>
        </div>
    </section>

    <!-- Methods Section -->
    <section class="detail_section" id="methods-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Methods & Insect-Specific Platform</h2>

                <div class="content_section">
                    <h3>Overview of the Insect-Specific Platform</h3>
                    <p>The insect-specific platform represents a paradigm shift in research methodology for pathogenic alphaviruses. This innovative approach leverages insect-specific viruses as the backbone for expressing alphavirus antigenic components, providing a safe, manageable system for detailed characterisation.</p>
                    
                    <div class="highlight_box">
                        <h4>Platform Advantages:</h4>
                        <p>• <strong>Biosafety:</strong> Limited replication in mammalian cells<br>
                        • <strong>Scalability:</strong> Easy production in insect cell culture<br>
                        • <strong>Flexibility:</strong> Capable of expressing multiple viral components<br>
                        • <strong>Reproducibility:</strong> Standardised, controllable system</p>
                    </div>
                </div>

                <div class="content_section">
                    <h3>Molecular Cloning Strategy</h3>
                    <p> Chimeras were generated using circular polymerase extension reaction (CPER)</p>
                    <ul>
                        <li><strong>Vector Modification:</strong> Insect-specific alphaviruses were used as the backbone for chimeric construct generation.</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Antigenic Characterisation Methods</h3>
                    <p>Multiple complementary techniques were employed:</p>
                    
                    <h4 style="margin-top: 1.5rem;">Enzyme-Linked Immunosorbent Assay (ELISA)</h4>
                    <ul>
                        <li>Detection of viral antigens using strain-specific and cross-reactive antibodies</li>
                        <li>Quantification of protein expression levels</li>
                        <li>Assessment of conformational epitopes</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">SDS-PAGE</h4>
                    <ul>
                        <li>Virus concentration was estimated using BSA standards.</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Neutralisation Assays</h4>
                    <ul>
                        <li>Testing against reference sera from vaccinated/infected individuals</li>
                        <li>Assessment of cross-reactivity between constructs</li>
                        <li>Evaluation of neutralising antibody potential</li>
                    </ul>
                </div>

            </div>
        </div>
    </section>

    <!-- Results Section -->
    <section class="detail_section" id="results-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Results</h2>

                <div class="content_section">
                    <h3>Antigenic Properties</h3>
                    
                    <h4 style="margin-top: 1.5rem;">ELISA Results</h4>
                    <p>Comparative antigenicity assessment revealed:</p>
                    <ul>
                        <li><strong>Pathogenic Constructs:</strong> High reactivity with strain-specific polyclonal antisera (OD₄₅₀ > 2.0)</li>
                        <li><strong>Chimeric Constructs:</strong> Reduced reactivity with parent strain antisera (OD₄₅₀ 0.8-1.5), indicating antigenic modification</li>
                        <li><strong>Cross-Reactivity:</strong> Modest cross-reactivity between chimeric constructs (≈40-60% of homologous signal)</li>
                        <li><strong>Reproducibility:</strong> Low inter-assay variability (CV < 10%) across independent experiments</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Immunofluorescence</h4>
                    <ul>
                        <li>Robust intracellular localisation at endoplasmic reticulum and Golgi apparatus</li>
                        <li>Punctate cytoplasmic distribution consistent with viral replication sites</li>
                        <li>Cell surface presentation observed, consistent with viral egress pathways</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Summary of Key Findings</h3>
                    <ul>
                        <li>✓ Successfully generated and propagated all viral constructs in insect cells</li>
                        <li>✓ Confirmed proper protein expression and maturation for both construct types</li>
                        <li>✓ Demonstrated distinct antigenic signatures between pathogenic and chimeric variants</li>
                        <li>✓ Established insect-specific platform as viable for alphavirus research</li>
                        <li>✓ Identified chimeric constructs as potential vaccine leads with safety enhancements</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Data Reproducibility</h3>
                    <p>All experiments were performed in triplicate with independent virus preparations. Inter-experiment variation was &lt;15% for most assays, confirming robust and reproducible results.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Future Section -->
    <section class="detail_section" id="future-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Future Directions</h2>

                <div class="content_section">
                    <h3>Vaccine Development Pipeline</h3>
                    <p>The findings from this antigenic characterisation study establish a robust foundation for advancing vaccine development:</p>
                    
                    <h4 style="margin-top: 1.5rem;">Short-term (1-2 years)</h4>
                    <ul>
                        <li><strong>Immune Response Studies:</strong> Immunisation of animal models (mice, guinea pigs) with chimeric constructs to assess humoral and cellular responses</li>
                        <li><strong>Challenge Studies:</strong> Evaluation of protective immunity against authentic alphavirus challenge</li>
                        <li><strong>Safety Assessment:</strong> Comprehensive toxicity and reactogenicity profiling</li>
                        <li><strong>Dose Optimisation:</strong> Establishing optimal immunisation schedules and antigen doses</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Medium-term (2-5 years)</h4>
                    <ul>
                        <li><strong>Preclinical Development:</strong> Advanced animal models (non-human primates) to predict human immune responses</li>
                        <li><strong>Formulation Development:</strong> Optimisation with adjuvants and delivery systems</li>
                        <li><strong>Manufacturing Scale-up:</strong> Transition from research scale to cGMP production</li>
                        <li><strong>Regulatory Engagement:</strong> IND-enabling studies and regulatory pathway definition</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Dissociation Constant (kd) Analysis</h3>
                    <p>While this project focused on antigenic characterisation, due to time limitations the project only focused on a limited panel of viruses, including: </p>
                    <ul>
                        <li>O'nyong'nyong Virus (ONNV) - closely related to Chikungunya</li>
                        <li>Mayaro Virus - emerging threat in South America</li>
                        <li>Sindbis Virus - model organism with clinical relevance</li>
                        <li>Semliki Forest Virus - well-characterised reference strain</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Applications</h3>

                    <h4 style="margin-top: 1.5rem;">Diagnostic Development</h4>
                    <ul>
                        <li>Recombinant antigens for serological testing</li>
                        <li>Reference reagents for quality control</li>
                        <li>Novel diagnostic platforms</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Antiviral Development</h4>
                    <ul>
                        <li>...</li>
                    </ul>

                </div>

                <div class="highlight_box">
                    <h4>Conclusion:</h4>
                    <p>This research establishes a critical foundation for understanding alphavirus antigenicity and vaccine development. The insect-specific platform offers a paradigm for safe, effective development of vaccines against dangerous pathogens, with immediate applications to alphavirus vaccines and broader potential for other emerging infectious diseases.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Footer -->
    <footer class="footer">
        <div class="footer_container">
            <div class="footer_section footer_brand">
                <h3 class="footer_title">Alphavirus Research Project</h3>
                <p class="footer_subtext">Antigenic Characterisation | SCIE3121</p>
            </div>
            <div class="footer_section">
                <h4>Quick Links</h4>
                <ul class="footer_links">
                    <li><a href="#home">Poster</a></li>
                    <li><a href="#background-section">Background</a></li>
                    <li><a href="#methods-section">Methods</a></li>
                    <li><a href="#results-section">Results</a></li>
                    <li><a href="#future-section">Future Work</a></li>
                </ul>
            </div>
        </div>
        <div class="footer_bottom">
            © 2025 SCIE3121 Research Project. All Rights Reserved.
        </div>
    </footer>

    <script src="script.js"></script>
</body>
</html>